HER2 Pan-Tumor Continent-Macau Expert Symposium

*For medical professionals for reading reference

ADC drugs have both antibodies and the strong lethality of high -active cytotoxic drugs, providing a brand new way for the "precise treatment" of tumors. In recent years, ADC drugs have been proven to be a very promising treatment method in tumors. Among them, ADC drugs for HER2 targets have continued to break through in the treatment of tumors such as breast cancer, gastric cancer, and non -small cell lung cancer.

Based on this, the ADC Academy Platform hosted by the Beijing Science and Technology Innovation Medical Development Foundation hosted the "HER2 Pan-Tumor" meeting to invite the mainland and Macau tumor experts to talk about new progress in physical tumor anti-HER2 treatment and share insights. This meeting will be held online on September 28, 2022 on a live broadcast. Professor Deng Yanhong and Professor Peng Xianghong are specially invited as the chairman of the conference. Professor Li Qiao, Professor Zhang Haibo, and Professor Zhao Lin As a guest of discussion, Professor Chen Kai, Professor Ganlu, Professor Qiu Hong and Professor Xue Yan, as a discussion guest, the treatment progress, future application prospects, and clinical practice of high -end dialogue ADC drugs in the field of gastric and breast cancer. Treat your participation and support!

Scan the QR code, welcome to watch the live broadcast

September 28th 19: 00-21: 30

Adc academy online

Hosted by the Beijing Science and Technology Innovation Medical Development Foundation, focusing on the academic exchange platform of antibody couplet drugs. The platform keeps pace with the latest progress in related fields and is committed to promoting the scientific exchanges and continuing medical education of relevant professionals.

*This article is only used to provide scientific information to medical people, and does not represent the viewpoint of this platform

- END -